Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Payables (2016 - 2025)

Historic Payables for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $40.6 million.

  • Ultragenyx Pharmaceutical's Payables rose 1273.41% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 1273.41%. This contributed to the annual value of $38.8 million for FY2024, which is 797.36% down from last year.
  • Ultragenyx Pharmaceutical's Payables amounted to $40.6 million in Q3 2025, which was up 1273.41% from $34.2 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Payables peaked at $59.8 million during Q2 2024, and registered a low of $15.6 million during Q3 2021.
  • For the 5-year period, Ultragenyx Pharmaceutical's Payables averaged around $35.2 million, with its median value being $36.0 million (2024).
  • Its Payables has fluctuated over the past 5 years, first surged by 15250.32% in 2022, then plummeted by 4274.58% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Payables stood at $17.1 million in 2021, then skyrocketed by 152.5% to $43.3 million in 2022, then decreased by 2.68% to $42.1 million in 2023, then dropped by 7.97% to $38.8 million in 2024, then rose by 4.69% to $40.6 million in 2025.
  • Its Payables was $40.6 million in Q3 2025, compared to $34.2 million in Q2 2025 and $47.4 million in Q1 2025.